Small-Cap Pharma Stock Plunges as US Regulatory Letter Wipes Out Rs 938 Crore in Market Cap—But It’s Not All Bad News
Small-Cap Pharma Stock Plunges as US Regulatory Letter Wipes Out Rs 938 Crore in Market Cap—But It’s Not All Bad News

Small-Cap Pharma Stock Plunges as US Regulatory Letter Wipes Out Rs 938 Crore in Market Cap—But It’s Not All Bad News

Despite the sharp decline, the regulatory setback isn't as severe as it seems—the letter only raises compliance concerns without halting operations or triggering an import alert.

DSIJ Intelligence Article rating: 5.0

Despite the sharp decline, the regulatory setback isn't as severe as it seems—the letter only raises compliance concerns without halting operations or triggering an import alert.

US Biosecure Act, China Plus One, and Trump’s Tariff War: CDMOs Are Hot Topic, As This Small-Cap Pharma Gains 2.66% on CDMO Expansion
US Biosecure Act, China Plus One, and Trump’s Tariff War: CDMOs Are Hot Topic, As This Small-Cap Pharma Gains 2.66% on CDMO Expansion

US Biosecure Act, China Plus One, and Trump’s Tariff War: CDMOs Are Hot Topic, As This Small-Cap Pharma Gains 2.66% on CDMO Expansion

Regulatory changes, such as the US Biosecure Act, may accelerate growth for CDMO businesses. However, uncertainties remain, especially if Donald Trump returns to power. Trump has criticized India on trade issues, including pharmaceutical tariffs, which could impact domestic pharma strategies.

DSIJ Intelligence Article rating: 5.0

Regulatory changes, such as the US Biosecure Act, may accelerate growth for CDMO businesses. However, uncertainties remain, especially if Donald Trump returns to power. Trump has criticized India on trade issues, including pharmaceutical tariffs, which could impact domestic pharma strategies.

230 per cent returns: This multibagger pharmaceutical company announced approval for a new drug from US FDA; do you own it?
230 per cent returns: This multibagger pharmaceutical company announced approval for a new drug from US FDA; do you own it?

230 per cent returns: This multibagger pharmaceutical company announced approval for a new drug from US FDA; do you own it?

The company has delivered returns of 14.5 per cent over the past 3 years and returns of 230 per cent over the past 5 years.

DSIJ Intelligence Article rating: 4.1

The company has a ROCE of 19.4 per cent and a ROE of 19.1 per cent.

Stocks to watch: These small-cap stocks will be in focus on Tuesday!
Stocks to watch: These small-cap stocks will be in focus on Tuesday!

Stocks to watch: These small-cap stocks will be in focus on Tuesday!

Among the BSE Smallcap gainers were Olectra Greentech, Rhi Magnesita India, Radhe Developers and Chemplast Sanmar.

DSIJ Intelligence Article rating: 4.2

On Monday, the Sensex fell by 175 points to close at 59,288.35, while the Nifty 50 dropped by 73 points to close at 17,392.70

Overnight Digest: Stocks likely to be in focus on August 1
Overnight Digest: Stocks likely to be in focus on August 1

Overnight Digest: Stocks likely to be in focus on August 1

Keep an eye on these stocks for Monday's trading session

DSIJ Intelligence Article rating: 4.4

On Friday, investors piled up the metal and IT shares, coupled with some major Sensex stocks like Reliance Industries, HDFC twins, Sun Pharma, and Bajaj Finance. The benchmark indices ended the trading session near the day's high level, closing the week on a green note. 

Stocks to watch: These smallcap stocks will be in focus tomorrow!
Stocks to watch: These smallcap stocks will be in focus tomorrow!

Stocks to watch: These smallcap stocks will be in focus tomorrow!

Nahar Capital and Financial Services, Sree Rayalaseema Hi-Strength Hypo, Linde India, Excel Industries, Kothari Products, Nahar Poly Films, Polyplex Corporation and Supreme Petrochem made a fresh 52-week high today.  

DSIJ Intelligence Article rating: 4.4

BSE Smallcap index outperformed broader markets, losing only 0.88 per cent and closing at 26,987.85.

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2025

Multibaggers31-Mar, 2025

Bonus and Spilt Shares31-Mar, 2025

Penny Stocks31-Mar, 2025

Multibaggers31-Mar, 2025

Knowledge

Knowledge28-Mar, 2025

General22-Mar, 2025

MF14-Mar, 2025

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR